https://www.globenewswire.com/news-release/2022/12/21/2577734/0/en/BioNTech-Starts-Phase-1-Clinical-Trial-for-Prophylactic-Herpes-Simplex-Virus-2-Vaccine-Candidate-BNT163.html
0
0
12/21/22 at 11:45am
Organization
GlobeNewswire
Author
BioNTech SE
First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate......
Create an account
or login to join the discussion